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S U M M A R Y
Background: Antiviral drugs are critical adjuncts to inﬂuenza vaccination. This study determined the in
vitro susceptibilities of inﬂuenza A and B viruses isolated in the 2010–2011 season in Russia to the
neuraminidase inhibitor oseltamivir and the hemagglutinin fusion inhibitor umifenovir and clinical
efﬁcacy of this antiviral drugs in this season.
Methods: The antiviral potency of these drugs against A(H1N1)pdm09 virus in mice was assessed.
Importantly, the clinical effectiveness of oseltamivir and umifenovir was evaluated in a retrospective
study conducted in 26 regions of Russia.
Results: All tested viruses (n = 36) were susceptible to oseltamivir and umifenovir in vitro. Oseltamivir
(10 mg/kg/day) and umifenovir (60 mg/kg/day) signiﬁcantly increased the survival of mice challenged
with A/California/04/2009 (H1N1)pdm09 virus (p < 0.05). Inﬂuenza infection was laboratory-conﬁrmed
in 442 patients among 1462 patients hospitalized with acute respiratory infections. The treatment of
inﬂuenza-infected patients within 48 h of symptom onset with oseltamivir and umifenovir was
associated with a signiﬁcant decrease in the duration of illness (2–3 days) and symptoms (p < 0.001).
Pneumonia was observed in none of the patients treated with oseltamivir and in 0.3% of the patients
treated with umifenovir, compared to 23.7% of patients who did not receive antiviral therapy (p < 0.001).
Conclusions: This study provided experimental and clinical evidence of the efﬁcacy of oseltamivir and
umifenovir against inﬂuenza viruses, representatives of which have continued to circulate in post-
pandemic seasons.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Inﬂuenza A and B viruses are the most common human
respiratory pathogens that cause annual epidemics with high
morbidity and signiﬁcant mortality. Occasionally inﬂuenza A
viruses have caused pandemic outbreaks affecting millions of
people worldwide. On June 11, 2009, the World Health Organiza-
tion (WHO) raised the global pandemic alert level to phase 6, the
pandemic phase, in response to the emergence and global spread of
a novel inﬂuenza A(H1N1)pdm09 virus that contained a previously
unseen combination of genes of swine origin.1 In Russia, from* Corresponding author. Tel.: +7 916 211 88 78; fax: +7 495 917 49-00.
E-mail address: wnyfd385@yandex.ru (I.A. Leneva).
http://dx.doi.org/10.1016/j.ijid.2016.01.001
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).2009 through 2011, it is estimated that the inﬂuenza virus caused
approximately 30.8 million cases of inﬂuenza annually.2,3
The ﬁrst pandemic of the 21st century emphasized the limited
available strategies for the control of inﬂuenza infections. The
prevention and treatment of inﬂuenza currently relies on vaccines
and antiviral agents. Although vaccines are the better option for
inﬂuenza control, their composition must be updated regularly to
reﬂect changes in the circulating viruses. The lesson learned from
the 2009 A(H1N1) pandemic is that, despite improvements in the
preparation of inﬂuenza vaccines, the current strategies for the
preparation of either inactivated or live-attenuated inﬂuenza
vaccines require more than 6 months. Consequently, vaccines were
not available to control the ﬁrst wave of the pandemic.3,4 In Russia,
a vaccine to the new A(H1N1)pdm09 virus was available for use
only at the beginning of 2010. Additionally, some people are not
adequately protected by vaccination.5,6 Consequently, effectiveciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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important adjunct to vaccination.
There are some anti-inﬂuenza drug classes that are licensed in
Russia. The membrane (M)2 ion channel inhibitors, including
rimantadine, are active against the inﬂuenza A virus, but their
clinical use is limited because they are not effective against the
inﬂuenza B virus and lead to the emergence of transmissible drug-
resistant strains.6,7 At the beginning of the pandemic, it was shown
that the A(H1N1)pdm09 viruses were resistant to amantadine and
rimantadine. The neuraminidase inhibitor oseltamivir (oral drug,
75 mg/dose; Tamiﬂu) is active against inﬂuenza A and B viruses
and binds to the neuraminidase (NA) surface glycoprotein of newly
formed virus particles, preventing their efﬁcient release from the
host cell.6,7
Umifenovir (arbidol; ethyl 6-bromo-4-[(dimethylamino)-
methyl]-5-hydroxy-1-methyl- 2-[(phenylsulfanyl)methyl]-1H-in-
dole-3-carboxylate hydrochloride monohydrate) was developed
by a joint consortium of Russian scientists from the Centre for Drug
Chemistry, Moscow, the Medical Radiology Scientiﬁc Research
Institute, Obninsk, and the Pasteur Scientiﬁc Research Institute for
Epidemiology and Microbiology, St. Petersburg.8,9 Umifenovir is a
broad-spectrum antiviral compound that blocks viral fusion.10–13 It is
manufactured in both the Russian Federation and China, where it is
licensed for use for the prophylaxis and treatment of inﬂuenza A and
B infections. Studies on its mechanism of action against the inﬂuenza
virus have shown that umifenovir falls within a class of inhibitors
that interact with hemagglutinin (HA) to stabilize it against the
low pH transition to its fusogenic state; consequently, it inhibits
HA-mediated membrane fusion during inﬂuenza virus infection.11,12
Umifenovir has strong antiviral activity against both inﬂuenza A and
B viruses in cell culture and in virus-infected mice.14–16 Clinical trials
conducted on more than 30 000 patients have shown that umifenovir
is well tolerated, and no side effects have been revealed.8,9 Arbidol-
resistant mutants have been generated in cell culture,13 but to date,
arbidol-resistant viruses have not been isolated from humans. There
is also no evidence of naturally occurring resistance to umifenovir in
any inﬂuenza virus isolates.17,18
On August 10, 2010, the WHO declared a worldwide post-
pandemic period. Similar to most other countries, the peak
inﬂuenza season during 2010–2011 in Russia was associated with
the co-circulation of three inﬂuenza viruses: A(H1N1)pdm09,
A(H3N2), and B. These three viruses were different in prevalence
and geographic location. A(H3N2) dominated in the Far East,
A(H1N1)pdm09 and B were observed in Siberia, and
A(H1N1)pdm09 was observed in the European region. On average,
the inﬂuenza virus activities during the 2010–2011 epidemic
period in Russia were as follows: A(H1N1)pdm09, 53.0%; A(H3N2),
7.0%; B, 40.0%. A detailed study of the epidemic antigenic
properties of the strains showed that most of the strains were
similar to the reference strains that were recommended for vaccine
composition for the 2010–2011 epidemic season, which included
A/California/07/2009 (H1N1)pdm09, A/Perth/16/2009 A(H3N2),
and B/Brisbane/60/2008 (8.0% of strains were similar to another
evolutionary line, B/Yamagata/16/88).17,18
The purpose of this study was to provide detailed information
regarding virus susceptibility and clinical effectiveness in a
retrospective pharmacoepidemiological study of oseltamivir and
umifenovir, which were licensed and used widely during the ﬁrst
post-pandemic 2010–2011 inﬂuenza season in Russia. The
experimental part of this study aimed to make recommendations
for the treatment and prophylaxis of inﬂuenza viruses that
circulated during this period, including the swine inﬂuenza
A(H1N1) virus. These data will also contribute to the monitoring
of antiviral resistance. The aim of the clinical observational
individual patient data study was to analyze the effectiveness of
antiviral use on inﬂuenza severity and outcomes.2. Materials and methods
2.1. Compounds
Oseltamivir carboxylate ((3R,4R,5S)-4-acetamido-5-amino-3-
(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid) and the pro-
drug oseltamivir phosphate (oseltamivir) (ethyl(3R,4R,5S)-4-acet-
amido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxyl-
ate) were generous gifts from Chemical Diversity Inc. (San Diego,
USA). The compounds were dissolved in sterile distilled water for
the in vitro and in vivo experiments.
Umifenovir (arbidol; ethyl 6-bromo-4-[(dimethylamino)methyl]-
5-hydroxy-1-methyl-2-[(phenylsulfanyl)methyl]-1H-indole-3-carbo-
xylate hydrochloride monohydrate) was a generous gift from Prof.
Glushkov. Umifenovir was dissolved to completion in 0.5 ml of
96-proof ethanol at 37 8C for 10 min, followed by dilution in 4.5 ml of
sterile distilled water. For each experiment, a freshly made stock
was used. This stock (1800 mM) was used for the preparation of the
required umifenovir concentrations for the cell culture experiments.
For oral delivery to mice, umifenovir was suspended in 1% starch.
2.2. Cells and viruses
Madin–Darby canine kidney (MDCK) cells were grown in
minimal essential medium (MEM) supplemented with 10% foetal
bovine serum (FBS), 5 mM L-glutamine, 25 mM HEPES, 100 U/ml
penicillin, 100 mg/ml streptomycin sulphate, and 100 mg/ml
kanamycin sulphate in a humidiﬁed atmosphere of 5% CO2.
Inﬂuenza A/Aichi/2/68 (H3N2) (mouse-adapted), as a reference
prototype strain, was obtained from the D.I. Ivanovsky Research
Institute of Virology, Moscow, Russian Federation. The A/Califor-
nia/04/2009 (A/CA/04/09) (H1N1)pdm09, A/Victoria/361/2011
(H3N2), and %/Wisconsin/1/2010 inﬂuenza viruses were provided
by the WHO Collaborating Centre for Reference and Research on
Inﬂuenza (St. Petersburg, Russia). Oseltamivir-resistant !/Perth/
265/2009 (H1N1pdm09) with the H275Y NA substitution (N1
numbering) and B/Perth/211/2010 with the D197E NA substitution
(B numbering) were obtained from the NIS Panel of Inﬂuenza A and
B Viruses for Assessment. Laboratory and vaccine strains of
inﬂuenza A and B viruses were grown in 9-day-old embryonated
chicken eggs. Clinical isolates were isolated and grown in MDCK
cells.
2.3. Virus susceptibility to an NA inhibitor, in vitro
A ﬂuorometric assay using the ﬂuorogenic substrate 20-(4-
methylumbelliferyl)-a-D-N-acetylneuraminic acid (MUNANA)
(Sigma-Aldrich) was used to determine viral NA activity.19 The
ﬂuorescence of the released 4-methylumbelliferone was measured
in a Varioskan multi-mode microplate reader (BioTek) using
excitation and emission wavelengths of 360 and 460 nm,
respectively. Serial 10-fold concentrations of oseltamivir carbox-
ylate (0.01 nM to 10 000 nM) were studied. The drug concentration
that inhibited 50% of the NA enzymatic activity (IC50) was
determined from the dose–response curve using GraphPad Prism
5.0 software. The results were reported as the average of three
experiments for each virus.
2.4. Umifenovir antiviral activity by ELISA assay
A modiﬁed ELISA was used to measure the inhibition of
inﬂuenza A and B virus replication in MDCK cells with
umifenovir.20 This assay detected the expression of viral proteins
(M+NP) on infected cells. Brieﬂy, MDCK cells were seeded in
96-well plates at 3000 cells per well in MEM containing 10% FBS,
100 U/ml penicillin, 100 mg/ml streptomycin sulphate, and
Table 1
List of primers for PCR/sequencing of the inﬂuenza virus target genes
Target
gene
Coverage of amino
acid region with
potential mutations
Primer
direction
Primer sequence
NA Ile 223 Arg
His 274 Tyr
Arg 292 Lys
Asn 294 Ser
F
R
ttgcttggtcggcaagtgc
ttttttgaacaaactacttgtcaa
NA Glu 119 Val F atgaatccaaatcaiaaiataaya
R caattcigactctigigtyct
HA Gln 27 Asn
Gln 42 His
Lys 51 Asn
Asn 117 Arg
F
R
attgccggtttcattgaag
ctgcactgcaaagacccattggagcaca
M (M2) Leu 26 Phe
Val 27 Ala
Ala 30 Thr
Ser 31 Asn
Gly 34 Glu
F
R
agcaggtagatattgaaaaatga
gtagaaacaaggtagttttttac
NA, neuraminidase; HA, hemagglutinin; F, forward; R, reverse.
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with 5% CO2 until 90% cell conﬂuency was reached. Then, the cells
were washed twice with serum-free MEM before infection. Each
microtitre plate included uninfected control wells, virus-infected
control wells, and virus-infected wells to which umifenovir was
added. Cells were overlaid with MEM (100 ml) containing 2.5 mg/
ml N-tosyl-L-phenylalanine chloromethyl ketone (TPCK)-treated
trypsin and serial 2-fold umifenovir dilutions (ﬁnal concentration
range, 1 mM to 30 mM). After incubation for 1 h at 37 8C, 100 ml of
virus-containing allantoic ﬂuid (approximately 0.1 PFU/cell) was
added to all wells, except the uninfected control wells. After
incubation for 18 h at 37 8C in a humidiﬁed atmosphere of 5% CO2,
the cells were washed and ﬁxed by adding 50 ml of cold 0.05%
glutaraldehyde in phosphate-buffered saline (PBS). Viral protein
expression was measured by ELISA, as described previously.20,21
The percentage inhibition of virus replication by umifenovir was
calculated after correcting for background (cell control) values as
follows: percentage inhibition = 100  [1  (OD450) treated sam-
ple/(OD450) virus control sample]. The IC50 value (i.e., the
concentration of compound required to inhibit virus replication
by 50%) was determined by plotting the percentage inhibition of
virus replication as a function of the compound concentration. The
results were reported as the average of three experiments for each
virus.
2.5. Genetic analysis of inﬂuenza A and B viruses
Identiﬁcation of molecular markers of drug resistance was carried
out by direct sequencing of the NA (neuraminidase), HA (hemagglu-
tinin), and M2 (membrane ion channel protein) gene segments of the
inﬂuenza viruses from the biological inﬂuenza-infected patient
samples. The species were collected from the Central, North-
Western, Southern, and Volga federal districts of Russia during the
2010–2011 inﬂuenza season. Autopsy material from inﬂuenza
patients and randomized nasopharyngeal swabs were taken for
surveillance and sent to the Central Research Institute for
Epidemiology (CRIE) reference centre for conﬁrmation and addition-
al investigation, from the laboratories of 23 Russian Federal Centres
of Hygiene and Epidemiology of Rospotrebnadzor. Nasopharyngeal
swabs and autopsy material (e.g., trachea, bronchus, lung, and spleen
fragments) were stored frozen (70 8C) until they were studied.
Conﬁrmation of inﬂuenza infection and the identiﬁcation of
inﬂuenza virus A(H1N1)pdm09 was done by real-time RT-PCR
with the AmpliSens Inﬂuenza Virus A/B-FRT PCR Kit and the
AmpliSens Inﬂuenza Virus A/H1-swine-FRT PCR Kit (CRIE, Rus-
sia),22 in accordance with the manufacturer’s instructions, on a
Rotor-Gene 6000 instrument (Corbett Research, Sydney, Australia).
Total RNA from the inﬂuenza-infected patient samples (nasopha-
ryngeal swabs or autopsy samples) was extracted using reagents
from the RIBO-prep Nucleic Acid Extraction Kit (AmpliSens, CRIE,
Russia). The REVERTA-L RT Reagents Kit (AmpliSens, CRIE, Russia)
was used for reverse-transcription of RNA. Ampliﬁcation of viral
cDNA from 108 inﬂuenza patient biological samples was
conducted using the primers listed in Table 1 on a Tercyc
thermocycler (DNA-Technology, Russia). PCR product sequencing
reactions were done with the same primers as used for
ampliﬁcation (Table 1) using the ABI PRISM Big Dye v.3.1 Cycle
Sequencing Reaction Kit, in accordance with the manufacturer’s
instructions, and were analyzed on an ABI PRISM 3100 Genetic
Analyzer (Applied Biosystems, USA). All sequences were assem-
bled using Lasergene version 10.1 (DNASTAR Inc., USA).
2.6. Assessment of drug efﬁcacy, in vivo
Female BALB/c mice weighing approximately 12–14 g were
quarantined and acclimated for 3 days prior to use. Mice weregroup-housed in cages and used at a quantity of 10 mice per
treatment group. Mice were lightly anesthetized and inoculated
intranasally with 10 MLD50 (mouse lethal dose) of mouse-adapted
A/California/04/2009 (H1N1)pdm09 virus in PBS (104 EID50 (50%
Egg Infective Dose)). Compounds were prepared in a 0.2-ml
volume. The treatments were administered to the mice for ﬁve
consecutive days, beginning 6 h before viral inoculation, by oral
gavage, using doses of 20, 30, and 60 mg/kg of body weight/day of
umifenovir, which was administered once daily (in the morning),
or doses of 2.5 and 10 mg/kg of body weight/day of oseltamivir,
which was given twice daily. The placebo was administered in
parallel with the antiviral treatments. Survival and weight changes
were observed for 21 days after virus inoculation. Animals that
showed signs of severe disease and weight loss of 25% were
humanely euthanized. The mice were weighed on days 0, 1, 2, 3, 4,
5, 7, 9, 11, 13, and 15 after infection, and the weight loss or gain was
calculated for each mouse as a percentage of its weight on day
0 before virus inoculation. The reported values are average
percentage changes in weight  standard errors (SEs). All studies
were approved by the Mechnikov Research Institute of Vaccines and
Sera Committee on the Ethics of Animal Experiments and were
conducted in strict accordance with the applicable laws and
guidelines.
2.7. Clinical effectiveness of antiviral use on inﬂuenza outcomes
2.7.1. Study design
The observational case–control clinical study was set up in the
2010–2011 season. The aim of the study was to analyze individual
patient data for the effectiveness of antiviral use on inﬂuenza
disease severity and outcomes.
2.7.2. Participants
The study population included adults (older than 18 years of
age) admitted to hospitals with acute respiratory viral infections
(ARVI) between July 2010 and May 2011 from 26 regions of the
Russian Federation. A total of 1462 patients were included in the
study. Data were collected from the routine medical records of
ARVI patients. The collected data included demographic informa-
tion, clinical observations (such as symptoms, chronic medical
conditions, treatment, and temperature), and laboratory test
results.
2.7.3. Case deﬁnition
A human ARVI case was clinically deﬁned as a combination of
fever (>37 8E) and one or more of the following symptoms: cough,
Table 2
Drug susceptibility of human inﬂuenza viruses that circulated during the 2010–
2011 season in Russia
Inﬂuenza virus Susceptibility to antiviral drugs
Oseltamivir
carboxylate
(mean IC50 SD,
nM)a
Umifenovir
(mean IC50 SD,
mM)a
Inﬂuenza A(H1N1) subtype
A/Puerto-Rico/8/1934b 2.02  0.75 10.8  0.55
A/Solomon Islands/03/2006b 1.23  0.56 10.8  0.75
A/California/04/2009b 0.94  0.13 7.2  0.75
A/California/07/2009b 0.99  0.43 7.5  0.68
A/Perth/265/2009 (H1N1)pdm09 1.00  0.068 9.1  0.75
A/Perth/265/2009 (H1N1)pdm09
H275Y oseltamivir-resistant
359.9  87.2 13.5  0.75
A/IIV-Vladimir/68/2011 8.02  0.5 12.9  0.7
A/IIV-Vladimir/69/2011 ND 16.5  0.7
A/IIV-Vladimir/35/2011 5.02  0.43 9.0  0.9
A/IIV-Vladimir/67/2011 ND 11.3  0.5
A/IIV-Moscow/27/2011 1.02  0.25 16.7  1.1
A/IIV-Moscow/40/2010 2.22  0.55 9.7  0.9
A/IIV-Moscow/88/2011 4.16  0.12 10.8  1.0
A/IIV-Moscow/70/2011 5.34  0.67 12.0  0.8
A/IIV-Moscow/38/2010 3.42  0.15 13.3  2.2
A/IIV-Moscow/13/2011 ND 16.2  2.1
A/IIV-Moscow/30/2011 4.56  0.45 14.2  1.5
A/IIV-Moscow/75/2011 2.15  0.71 9.9  0.8
A/IIV-Moscow/74/2011 2.86  0.325 9.5  0.1
A/IIV-Moscow/39/2010 7.34  0.33 9.9  0.3
A/IIV-Moscow/1/2011 8.32  0.75 11.3  1.6
A/IIV-Moscow/3/2011 7.51  0.77 13.6  2.4
A/IIV-Moscow/26/2011 2.99  0.23 9.0  0.7
A/IIV-Moscow/38/2011 10.12  0.22 12.8  2.1
A/IIV-Moscow/37/2011 9.56  0.73 9.0  0.5
A/IIV-Moscow/28/2011 ND 9.0  0.2
A/IIV-N. Novgorod/66/2011 8.15  0.22 13.5  1.7
A/IIV-N. Novgorod/60/2011 7.08  0.87 13.55  0.4
A/IIV-Moscow/45/2011 6.09  0.35 13.6  1.2
A/IIV-Moscow/43/2011 6.99  0.77 19.8  2.0
A/IIV-Moscow/4/2011 ND 10.6  1.0
A/IIV-Cheboxary/71/2011 5.12  0.34 13.5  1.8
Inﬂuenza A(H3N2) subtype
A/Victoria/361/2011b 1.89  0.19 8.1  0.4
A/Aichi/2/1968b 0.43  0.24 13.5  0.3
A/Perth/16/2009b 0.92  0.01 9.5  2.1
A/Vladivostok/28/2011 0.98  0.05 13.5  1.4
A/Vladivostok/22/2011 2.31  0.15 11.3  1.1
A/Vladivostok/21/2011 2.56  0.23 16.5  2.3
A/Vladivostok/27/2011 ND 23.0  2.9
A/Vladivostok/4/2010 0.99  0.07 21.8  2.7
A/Vladivostok/1/2010 1.91  0.11 13.5  0.9
Inﬂuenza B viruses
B/Brisbane/60/2008b 25.42  0.51 17.1  0.4
B/Wisconsin/2010b 21.29  0.48 14.4  1.2
B/Perth/211/2001 19.24  2.43 9.0  0.7
B/Perth/211/2001 (D197E)
oseltamivir-resistant
230.3  62.6 (4) 10.8  0.5
B/Vladivostok/21/2011 25.61  0.22 18.1  1.3
B/Vladivostok/27/2011 20.44  2.44 19.8  2.4
B/Moscow/70/2011 25.31  0.68 17.4  0.8
B/Moscow/38/2011 23.46  0.55 18.7  2.3
IC50, the drug concentration that inhibits 50% of the NA enzymatic activity; SD,
standard deviation; ND, not done.
a The results are reported as the average of three experiments for each virus.
b Reference laboratory strain or reference vaccine strain.
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were deﬁned as FLU-positive when the PCR (AmpliSens1 Inﬂuenza
virus A/B, Russia) or ELISA (NovaLisa1, NovaTec, Germany) results
from the throat swab samples were positive for inﬂuenza A or B
virus.
2.7.4. Statistical analyses
The data were analyzed using Microsoft Excel 2007; simple
proportions, means and standard deviations (SD) were calculated.
Unpaired t-tests were applied. In other cases, the Mann–Whitney
U-test and Chi-square test were used. A p-value below 0.05 was
considered to indicate signiﬁcance in all tests.
3. Results
3.1. In vitro drug susceptibility of human inﬂuenza viruses circulating
during the 2010–2011 season
Based on the results received from two Russian national
inﬂuenza centres, 969 inﬂuenza strains were isolated during the
2010–2011 season in different regions of Russia, of which 586
(60.4%) were typed as inﬂuenza A viruses and 383 (39.6%) as
inﬂuenza B viruses. Of the sub-typed inﬂuenza A viruses, 521
(88.9%) were inﬂuenza A(H1N1)pdm09 and 65 (11.1%) were
inﬂuenza A(H3N2). Among these, 36 strains were studied with
respect to their susceptibility to umifenovir and 30 strains were
studied for their susceptibility to oseltamivir carboxylate.
Virus isolate susceptibility to anti-inﬂuenza drugs (oseltamivir
carboxylate and umifenovir) was studied and compared to
laboratory and vaccine reference strains from the 2010–2011
season. A/Puerto-Rico/8/1934(H1N1), A/Solomon Islands/03/
2006(H1N1), A/California/04/2009(H1N1)pdm09, and A/Califor-
nia/07/2009(H1N1)pdm09 were used as controls for the H1N1
inﬂuenza A virus isolates; A/Aichi/2/1969(H3N2) and A/Victoria/
361/2011(H3N2) were used as controls for the H3N2 inﬂuenza A
virus isolates; B/Brisbane/60/2008, B/Wisconsin/2010, and B/
Perth/211/2001 were used as controls for the inﬂuenza B virus
isolates. In addition, the oseltamivir-resistant viruses A/Perth/265/
2009 (H1N1)pdm09, which possesses an H275Y substitution, and
B/Perth/211/2001, which possesses a D197E substitution, were
used as controls. The IC50 values for oseltamivir carboxylate and
umifenovir of the tested viruses are listed in Table 2.
Susceptibility of the virus isolates to oseltamivir carboxylate
was assessed with a ﬂuorescent NA inhibition assay. All tested
virus isolates exhibited IC50 values that were characteristic of
oseltamivir carboxylate-susceptible inﬂuenza viruses (Table 2).
The IC50 for oseltamivir carboxylate ranged from 0.94  0.13 nM to
10.12  0.22 nM for the inﬂuenza A strains and from 20.44  2.44 to
25.61  0.22 nM for the inﬂuenza B strains. Nevertheless, the IC50
values for the inﬂuenza B strains were 2.5- to 20-fold higher than
those obtained for the inﬂuenza A strains, and they fell within the
range that was previously observed for susceptible laboratory and
clinical isolates. In contrast, the A/Perth/265/2009(H1N1)pdm09
(H275Y) and B/Perth/211/2001 (D197) viruses had a signiﬁcantly
reduced susceptibility to oseltamivir carboxylate (359- and 12-fold
increases, respectively) compared with the susceptibility of the A/
Perth/265/2009 (H1N1)pdm09 and B/Perth/211/2001 wild-type
strains and all of the studied clinical isolates.
Susceptibility of the isolated viruses to umifenovir was
evaluated using an ELISA-based cell assay, which is considered a
standard protocol for testing antiviral activity of umifenovir
in vitro (Table 2). All isolates were equally susceptible to
umifenovir, with IC50 values ranging from 7.2  0.75 to
23.0  2.9 mM, and similar IC50 values were observed for the
susceptible laboratory and vaccine reference strains of the inﬂuenza
A and B viruses. Importantly, in these experiments, the wild-typeA/Perth/265/2009 (H1N1pdm09) and B/Perth/211/2001 inﬂuenza
viruses and their oseltamivir-resistant mutants were susceptible to
umifenovir at similar levels.
3.2. Efﬁcacy of oseltamivir and umifenovir in mice inoculated with the
A/California/07/2009 (H1N1)pdm09 virus
At the beginning of the pandemic, there were no data regarding
the efﬁcacy of antivirals against the new pandemic
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During the 2010–2011 inﬂuenza season, inﬂuenza
A(H1N1)pdm09, A(H3N2), and B viruses co-circulated, and
A(H1N1)pdm09 was absolutely prevalent. It was shown that
without prior host adaptation, the A/California/07/2009
(H1N1)pdm09 and A/California/04/2009 (H1N1)pdm09 inﬂuenza
viruses did not kill mice,23,24 which displayed only a transient
weight reduction (up to 11%). To estimate the efﬁcacy of the
antivirals, the A/California/07/2009 (H1N1)pdm09 virus was
adapted to mice through three passages in the mouse lungs, and
this virus was then used in the experiments. The efﬁcacy of
oseltamivir and umifenovir was studied in mice infected with the
10 MLD50 mouse-adapted A/California/07/2009 (H1N1)pdm09
virus. A high mortality rate (100%) and loss of body weight (21%)
were observed after viral infection.
Of the three umifenovir regimens (20, 30, and 60 mg/kg/day),
signiﬁcantly enhanced survival (p < 0.05) was observed only in
mice that received 60 mg/kg/day (Figure 1A). The survival rate rose
constantly when the dose was gradually increased. Umifenovir
administration in 60 mg/kg/day doses signiﬁcantly increased the
survival rate (50%) and time to death compared with untreated
control mice. Additionally, umifenovir treatment at all doses
studied prevented the weight loss (Figure 1B).
Oseltamivir was effective against A/California/07/2009
(H1N1)pdm09 virus infections at all dosages investigated.
Oseltamivir treatments at 2.5 mg/kg/day protected 40% of the
infected animals, prevented weight loss (Figure 1), and resulted in
a mean survival time of 13.9 days compared with 7.5 days in the
untreated control mice. The most profound therapeutic effect was
observed for oseltamivir at 10 mg/kg/day. Oseltamivir administra-
tion (10 mg/kg/day) completely protected the infected mice from
death and prevented weight loss (Figure 1).
3.3. Genetic analyses of inﬂuenza viruses
Data from 108 patients with inﬂuenza A(H1N1)pdm09 virus
infection during the 2010–2011 inﬂuenza season were analyzed.
Sequences are available from the GenBank database (JN185093.1–
JN185139.1, JN714484.1–JN714487.1, JN714492.1–JN714550.1).
All specimens tested contained the S31N mutation in the M2
protein, which confers cross-resistance to the adamantane class of
anti-inﬂuenza drugs.25 Mutations that led to an amino acid
substitution at H275Y in the NA protein, which cause resistance ofFigure 1. The effect of oseltamivir and umifenovir treatments on survival rates (A) and we
virus.the A(H1N1)pdm09 inﬂuenza virus to oseltamivir, were found in
three of the 108 samples (2.8% of patients). No mutations that led
to amino acid substitutions in the HA2 protein, which cause
resistance of the inﬂuenza A virus to umifenovir,11 were found in
the 108 samples tested.
3.4. The clinical effectiveness of antiviral medications
3.4.1. Clinical characteristics of acute respiratory tract infection
(ARTI) patients who tested positive for inﬂuenza virus
Of the 1462 hospitalized patients who met the ARTI case
deﬁnition criteria, 442 (30%) were positive for inﬂuenza viruses
(FLU-positive); inﬂuenza viruses were not detected in 1020 cases
(70%) (FLU-negative). The presence of inﬂuenza A viruses was
conﬁrmed in 339 cases, which included 177 with the
A(H1N1)pdm09 virus and 162 with the H3N2 virus. One hundred
and three patients were positive for the inﬂuenza B virus. The other
cases (n = 1020) included patients with ARTIs of an aetiology other
than viral (38/1020, 3.7%), cases in which a viral aetiology was not
detected (282/1020, 27.7%), and those for whom laboratory
conﬁrmation was not performed (699/1020, 68.5%). All variables
and analyzed data of the FLU-positive patients are shown in
Table 3.
3.4.2. Clinical effectiveness of antiviral medications on symptom
duration and inﬂuenza outcome
Only 24.8% of patients (110/442) received antivirals (umifeno-
vir 200 mg four times a day for 5 days, or oseltamivir 75 mg twice
daily for 5 days) within 48 h of symptom onset. Fifty-seven percent
of patients (252/442) received antiviral drugs at more than 48 h
after symptom onset. A comparative analysis of the effectiveness of
early and late antiviral treatment revealed that patients with non-
complicated inﬂuenza who received antiviral drugs within 48 h of
symptom onset had a shorter overall illness duration by a mean of
2.8 days (8.9 days vs. 11.7 days, p < 0.001), a shorter duration of
fever by a mean of 2.2 days (3.5 vs. 5.7 days, p < 0.001), and a
shorter duration of common symptoms by a mean of 2.6 days
(4.6 vs. 7.2 days, p < 0.001) and catarrhal symptoms by a mean of
3.3 days (5.5 vs. 8.8 days, p < 0.001), compared with patients who
received antiviral drugs at later than 48 h (n = 252) (Table 4 ).
The effectiveness of therapy in groups of patients who received
early treatment with umifenovir (55 of 110 patients) or early
treatment with oseltamivir (55 of 110 patients) were comparedight loss (B) in mice infected with the mouse-adapted A/California/07/2009 (H1N1)
Table 3
Clinical characteristics of patients admitted to hospitals with inﬂuenza between
July 2010 and May 2011
Clinical characteristics Inﬂuenza-positive
patients (n = 442)
Demographics
Age, years, mean  SD 34.2  14.6
Sex, male 37.6%
Comorbidity
Patients with BMI >30 kg/m2 10.2%
Patients with chronic diseases 43.7%
Pregnant women 19.6%
Clinical presentation
Common symptoms
Temperature, 8C, mean  SD 38.4  0.8
Temperature >39 8C 16.2%
Headache 63.1%
Myalgia 46.6%
Ocular injection 33.0%
Respiratory symptoms (catarrhal)
Cough 89.1%
Rhinorrhoea 33.9%
Sore throat 45.0%
Laboured breathing 12.0%
ARTI, acute respiratory tract infection; SD, standard deviation; BMI, body mass
index.
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treatment (Table 5). The overall duration of illness (8.47 vs.
11.31 days) and duration of main symptoms, including fever
(3.67 vs. 4.97 days) and catarrhal symptoms (5.25 vs. 7.75 days),
was lower in the umifenovir treatment group than in the group of
patients who received no antiviral therapy (p < 0.001). Similar
data were observed for patients treated with oseltamivir:
oseltamivir therapy within 48 h of symptom onset signiﬁcantly
reduced the total disease duration (8.35 vs. 11.31 days) and the
main symptoms, fever (3.05 vs. 4.97 days) and catarrhal
phenomena (4.4 vs. 7.75 days), compared with the patients didTable 5
Inﬂuence of antiviral drugs on the duration of inﬂuenza symptomsa
Clinical presentations Umifenovir
(n = 55)
Ose
(n =
Time from symptom onset to antiviral treatment order, days 0.82  0.39 0.75
Length of hospital stay, days 8.47  1.83c 8.35
Overall illness duration, days 3.67  1.59c 3.05
Fever duration, days 4.51  1.46c 4.27
a Data are presented as the mean  standard deviation.
b p-Value 1: umifenovir-treated group compared to placebo-treated control group; p
Value 3: oseltamivir-treated group compared to umifenovir-treated group.
c Statistically signiﬁcant difference.
Table 4
Clinical effectiveness of antiviral therapy on overall symptom duration
Clinical presentation (mean  SD) days Early antiviral 
(umifenovir or 
therapy started
from disease on
Time from symptom onset to antiviral treatment order 0.79  0.41b
Length of hospital stay 8.09  2.79 
Overall duration of illness 8.88  2.82b
Duration of fever 3.49  1.47b
Duration of catarrhal symptoms 5.51  3.18b
SD, standard deviation.
a Level of signiﬁcant differences between groups.
b Statistically signiﬁcant difference between early and late antiviral therapy groups.not receive any antiviral therapy (p < 0.001). No signiﬁcant
differences were found in the duration of illness and main
symptoms of inﬂuenza between the umifenovir and oseltamivir
treatment groups.
Pneumonia as a complication of inﬂuenza was observed in 0.3%
of the patients treated with umifenovir, in 23.7% of the patients
who did not receive antiviral therapy (p < 0.001), and in none of
the patients treated with oseltamivir.
The results showed that antiviral treatment with umifenovir
and oseltamivir within 48 h of symptom onset signiﬁcantly
decreased the durations of illness and symptoms by 2–3 days.
4. Discussion
In Russia, antiviral drugs are approved by the Ministry of Health
to treat or prevent inﬂuenza virus infections. The most widely used
drugs are the NA inhibitor oseltamivir and the fusion inhibitor
umifenovir. In this study, the in vitro susceptibility of inﬂuenza A
and B viruses that circulated during the 2010–2011 season to
oseltamivir carboxylate and umifenovir was evaluated. Similar to
most other countries, the peak inﬂuenza season from 2010–2011
in Russia was associated with the co-circulation of
A(H1N1)pdm09, A(H3N2), and B viruses. The data from the
present study showed that the IC50 values of oseltamivir
carboxylate and umifenovir for all tested A(H1N1)pdm09,
A(H3N2), and B virus isolates from the 2010–2011 inﬂuenza
season were comparable to those for the human susceptible
viruses. Notably, umifenovir inhibited the replication of both
oseltamivir-susceptible and oseltamivir-resistant viruses. Therapy
with oseltamivir resulted in a lower frequency of emergence of
drug-resistant variants.26 However, during the 2008–2009 inﬂu-
enza season, oseltamivir-resistant A(H1N1) viruses with an H275Y
NA substitution spread globally.27 Since the ﬁrst wave of the
2009 pandemic, the overall level of oseltamivir resistance among
A(H1N1)pdm09 variants has remained relatively low (1%).28
However, as drug-resistant variants continue to emerge naturally
and through the selective pressure applied by antiviral drug use,ltamivir
 55)
No antiviral treatment
(n = 48)
p-Value 1b p-Value 2b p-Value 3b
  0.44 - - - 0.358
  2.47c 11.31  4.36 0.003 <0.001 0.125
  1.22c 4.96  2.31 0.019 <0.001 0.023
  1.72c 6.73  3.79
(n = 41)
0.001 <0.001 0.5
-Value 2: oseltamivir-treated group compared to placebo-treated control group; p-
therapy
oseltamivir
 at 48 h
set) (n = 110)
Late antiviral therapy
(umifenovir or oseltamivir
therapy started at >48 h
from disease onset) (n = 252)
p-Valuea
3.37  2.06 <0.001
8.63  3.84 (n = 249) 0.694
11.72  4.51 (n = 251) <0.001
5.67  3.13 <0.001
8.77  5.08 <0.001
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demonstrated that oseltamivir-resistant viruses are susceptible to
umifenovir, and this suggests that umifenovir may be a good
alternative for the clinical treatment of infection caused by
oseltamivir-resistant viruses. These ﬁndings are in correlation
with reports that have shown umifenovir to effectively inhibit the
replication of A/California/4/2009, A/California/7/2009 A(H1N1),
and other A(H1N1)pdm09 viruses that were isolated from patients
in 2009.15,29,30
The data obtained in vitro were conﬁrmed in animal studies. It
has been shown previously that oseltamivir is effective in mice and
ferrets infected with the A/California/04/2009 (H1N1)pdm09
virus.23,31 Prior to the current study, there were no data regarding
the efﬁcacy of umifenovir against the A(H1N1)pdm09 virus in
animal models. The present study conﬁrmed the ﬁndings
regarding the high efﬁcacy of oseltamivir at a dose 10 mg/kg/
day in mice against the A(H1N1)pdm09 inﬂuenza virus.31 It was
also found that umifenovir at a dose 60 mg/kg/day was effective in
mice infected with the A/California/04/2009 (H1N1)pdm09 virus,
increased the survival rate (60%), and completely prevented
weight loss as compared with untreated virus-inoculated control
mice. In contrast, low doses of umifenovir only prevented weight
loss and did not sufﬁciently affect the survival rate or mean days to
death. This study is the ﬁrst, to the authors’ knowledge, to assess
the effectiveness of umifenovir against pandemic A(H1N1)
inﬂuenza virus infection in vivo.
Sequence analysis of the clinical samples identiﬁed the
presence of the H275Y NA mutation, which is known to confer
resistance to oseltamivir, in three specimens among the 108 speci-
mens tested. The frequency of oseltamivir resistance in patients
with the inﬂuenza A(H1N1) virus in the present study was
consistent with that in a WHO report published during this
period.28 Among the 108 specimens from the 2010–2011 season,
no HA amino acid changes that have previously been identiﬁed in
vitro as being associated with reduced susceptibility to umifenovir
were found. These data correlate with those of previous
studies.17,18 To date, umifenovir-resistant mutants have only been
generated through serial passages in cell culture under drug
pressure. All mutants had different amino acid substitutions in the
HA2 subunit of the HA glycoprotein. Although umifenovir has been
used clinically for 30 years in Russia, drug-resistant viruses have
not yet been isolated in the clinic. Burtseva et al. tested over
700 clinical inﬂuenza A and B viruses that were isolated during
2002–2014 for their susceptibility to umifenovir in cell culture.
There was no evidence of naturally occurring resistance to
umifenovir in any of the tested isolates.17,18
The clinical retrospective observational study demonstrated
that the timing of initiation of the antiviral treatment relative to
the onset of illness is an important consideration in observational
studies that assess antiviral efﬁcacy. First, the treatment effective-
ness was compared between patients who received the antiviral
agents within 48 h of symptom onset and those who received the
antiviral drugs later than 48 h after symptom onset. The priority of
early treatment was demonstrated, and these data are in
agreement with those reported from other experimental and
clinical studies and the widely held concept that early initiation of
antiviral therapy is important to obtain effective control of viral
replication and, in turn, to shorten the duration of symptoms.32
Second, the effectiveness of oseltamivir and umifenovir was
compared. For the primary endpoints, the time to symptom
alleviation was not signiﬁcantly different between the oseltamivir
and umifenovir treatments. At present, oseltamivir is the gold
standard and the most widely used anti-inﬂuenza drug, with
proven efﬁcacy against inﬂuenza A and B infections. Clinical trials
with umifenovir in more than 30 000 patients were conducted in
the former Soviet Union during 1980–1990.8,9 The present study isthe ﬁrst to compare the clinical effectiveness of oseltamivir and
umifenovir. It was demonstrated that the effectiveness of
umifenovir treatment is comparable to that of the standard
anti-inﬂuenza oseltamivir treatment and this is a welcome
addition to the previous clinical trial data regarding umifenovir
effectiveness for the treatment of inﬂuenza A and B infections.
These data are encouraging for the current ongoing double-blind,
randomized, placebo-controlled clinical trial for umifenovir that
was initiated in 2012. The aim of that trial is to evaluate the efﬁcacy
and safety of umifenovir for the treatment and prophylaxis of
inﬂuenza and other ARVIs.33
Recent meta-analysis studies have shown that there is no
evidence that oseltamivir reduces the likelihood of complications,
particularly hospitalization, pneumonia, or the combined out-
come of pneumonia and mortality, in an intention-to-treat (ITT)
population.34–36 However, these studies have some limitations.
These works excluded many observational studies that found
oseltamivir to be helpful in normal clinical settings.37 The
evidence from randomized clinical trials (RCTs) was further
limited by the lack of high-quality evidence for patient-important
outcomes under the treatment of speciﬁc subgroups, including
hospitalized and immune-compromised patients. Data obtained
from RCTs among high-risk patients were limited by the actual
small number of these patients.36 Observational studies may
provide more information in addition to data currently available
from RCTs for certain elements of antiviral treatment. This beneﬁt
was reported in detail in a recent review.37 To supplement the
information from RCTs, the authors conducted a systematic
review of observational studies of antiviral treatment for
inﬂuenza. These observational studies suggested that oseltamivir
may reduce mortality, hospitalization, and symptom duration.
Evidence from some observational studies has also suggested that
oral oseltamivir treatment results in fewer complications, such as
pneumonia, otitis media, and any recurrent cardiovascular
outcome.38
Similar data were obtained in the present observational study,
which estimated the clinical effectiveness of oseltamivir and
umifenovir during the 2010–2011 inﬂuenza season in Russia.
There are some mismatches between the results of the meta-
analysis studies with the highest level of evidence and the results
of observational studies, such as the level of evidence, which is not
notably high, but the conditions are close to those of real clinical
situations. This condition does not allow deﬁnitive conclusions to
be drawn about the beneﬁt of antiviral treatments in individuals
and on inﬂuenza outcomes. Further high-quality RCT evidence is
needed to address important patient outcomes (e.g., mortality and
complications) and include hospitalized inﬂuenza patients. The
extrapolation of the results of such studies to the real clinical
situation is limited. Thus, observational studies are important and
additional tools that should be taken into consideration when
estimating the effectiveness of antiviral therapy.
Overall, the observational study results regarding the effective-
ness of oseltamivir and umifenovir during the 2010–2011
inﬂuenza season are concordant with the experimental data
regarding the high susceptibility of inﬂuenza viruses that
circulated during this period to these antivirals. The sequence
analysis did not reveal mutations that are associated with
resistance to umifenovir, but the H275Y NA mutation responsible
for resistance to oseltamivir was found (3/108, 2%). As it is not
possible to conduct placebo-controlled clinical trials for antiviral
effectiveness in inﬂuenza-infected patients every season, such
studies may be used to inform clinical and public health practices.
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